James Sexton
Brooklyn, NY

James Sexton

Data Scientist and Commercial Leader in the Pharmaceutical Industry

Read publications→Google ScholarLinkedInGitHub
01 — About
Portrait of James D. Sexton

A passion for patients
reaching back to the basic science

I started my career in academic neuroscience — specializing in brain imaging work at Imperial College London and UAB. Four papers, one in Nature Medicine.

I moved into industry to help build out the data side of an early clinical-stage startup. Since then I've worked across data science and commercial analytics for companies bringing new psychiatric therapeutics to market.

◆ cyclist◆ musician◆ backpacker
02 — Work

A path from lab to launch

  1. Now
    Compass Pathways
    Commercial Analytics
  2. 2022 — 2026
    Otsuka Precision Health
    Data Scientist
  3. 2021 — 2022
    Eleusis Therapeutics (now AtaiBeckley)
    Data Scientist
  4. 2020 — 2022
    Imperial College London
    Research
  5. 2017 — 2020
    University of Alabama at Birmingham
    Research
03 — Publications

Selected work

All on Google Scholar →
  1. 2022

    Increased global integration in the brain after psilocybin therapy for depression

    R. E. Daws, C. Timmermann, B. Giribaldi, J. D. Sexton, M. B. Wall, D. Erritzoe, L. Roseman, D. Nutt, R. Carhart-Harris

    Nature Medicine
    28(4), 844-851
  2. 2021

    Associations between lifetime classic psychedelic use and markers of physical health

    O. Simonsson, J. D. Sexton, P. S. Hendricks

    Journal of Psychopharmacology
    35(4), 447-452
  3. 2020

    Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics

    J. D. Sexton, C. D. Nichols, P. S. Hendricks

    Frontiers in Psychiatry
    10, 896
  4. 2019

    Prevalence and epidemiological associates of novel psychedelic use in the United States adult population

    J. D. Sexton, M. S. Crawford, N. W. Sweat, A. Varley, E. E. Green, P. S. Hendricks

    Journal of Psychopharmacology
    33(9), 1058-1067
04 — Contact

Get in touch

Best on LinkedIn. I'm slow to reply to recruiter outreach, quick to reply to anything involving bringing better options to patients, real-world evidence, commercial data.

LinkedIn→GitHub